Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

The authors report on the first controlled experiment to examine the memory-enhancing effects of posttraining methylene blue administration on retention of fear extinction and contextual memory following fear extinction training.

Incidental contextual memory was assessed 1 and 30 days after training to assess the cognitive-enhancing effects of methylene blue independent of its effects on fear attenuation.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Methylene blue (non-peptide stack partner), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Methylene blue (non-peptide stack partner) could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Combined Modality Therapy, Extinction, Psychological, Fear, Memory, Methylene Blue, Nootropic Agents and Phobic Disorders.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Methylene blue (non-peptide stack partner).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (The American journal of psychiatry), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.